ometendoОжирение и метаболизмObesity and metabolism2071-87132306-5524Endocrinology Research Centre10.14341/omet201223-10ometendo-6539Research ArticleСтатьиArticlesИнкретины и их влияние на течение сахарного диабета 2 типа у пациентов с морбидным ожирением после бариатрических операцийIncretins and their influence on the course of type 2 diabetes in patients with morbid obesity after bariatric operDedovI Ilibr@endocrincentr.ruYashkovYu IYashkov@celt.ruErshovaE VYu99pol06@rambler.ru20121506201292№2 (2012)310Copyright © Dedov I.I., Yashkov Y.I., Ershova E.V., 20122012Dedov I.I., Yashkov Y.I., Ershova E.V.Dedov I.I., Yashkov Y.I., Ershova E.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.omet-endojournals.ru/jour/article/view/6539

Большинство исследователей подтверждают значимую роль инкретинов, особенно глюкагон-подобного пептида-1, в улучшении метаболического контроля у пациентов с сахарным диабетом 2 типа (СД2) после бариатрических операций, в основном шунтирующих. О положительном влиянии бариатрических операций на течение СД2 известно из многочисленных публикаций, посвященных результатам хирургического лечения морбидного ожирения.

Most researchers support the important role of incretins, particularly glucagon-like peptide-1 in improving metabolic control in patients with type 2 diabetes after bariatric operations, mostly involving shunting. A positive effect of bariatric surgery for type 2 diabetes is known from numerous publications on the results of surgical treatment of morbid obesity and in this review we try to analyze the mechanisms of this effect.

морбидное ожирениесахарный диабет 2 типабариатрические операцииинкретиныmorbid obesitytype 2 diabetesbariatric surgeryincretinsReferencesЯшков ЮИ. Эффективность хирургических методов лечения ожирения при сахарном диабете II типа. Хирургия 2000;12:49-54.Яшков ЮИ. Эффективность хирургических методов лечения ожирения при сахарном диабете II типа. Хирургия 2000;12:49-54.Вaggio L, Drucker D. Biology of incretins: GLP-1 and GIP. Gastroenterology 2007;132:2131-57.Вaggio L, Drucker D. Biology of incretins: GLP-1 and GIP. Gastroenterology 2007;132:2131-57.Bailey C, Wilkes L, Conlon J. et al. Effects of gastric inhibitory polypeptide, vasoactive intestinal polypeptide and peptide histidine isoleucine on the secretion of hormones by isolated mouse pancreatic islets. J Endocrinology 1990;125:375-79.Bailey C, Wilkes L, Conlon J. et al. Effects of gastric inhibitory polypeptide, vasoactive intestinal polypeptide and peptide histidine isoleucine on the secretion of hormones by isolated mouse pancreatic islets. J Endocrinology 1990;125:375-79.Bayliss W, Starling E. The mechanism of pancreatic secretion. J Physiol 1902;28:325-53.Bayliss W, Starling E. The mechanism of pancreatic secretion. J Physiol 1902;28:325-53.Bollag R, Zhong Q, Ding K. et al. Glucose-dependent insulinotropic peptide is an integrative hormone with osteotropic effects. Mol Cell Endocrinol 2001;177:35-41.Bollag R, Zhong Q, Ding K. et al. Glucose-dependent insulinotropic peptide is an integrative hormone with osteotropic effects. Mol Cell Endocrinol 2001;177:35-41.Brown J, Dryburgh J. Gastric Inhibitory Polypeptide. II. The complete amino acid sequence. Can. J. Biochem 1971;49:867-72.Brown J, Dryburgh J. Gastric Inhibitory Polypeptide. II. The complete amino acid sequence. Can. J. Biochem 1971;49:867-72.Buchwald H, Avidor Y, Braunwald E. et al. Bariatric surgery: a systematic review and meta-analysis. JAMA 2004;292:1724-37.Buchwald H, Avidor Y, Braunwald E. et al. Bariatric surgery: a systematic review and meta-analysis. JAMA 2004;292:1724-37.Buchwald H, Estok R, Fahrbach K. et al. Trends in mortality in bariatric surgery: a systematic review and meta-analysis. Surgery 2007;142:621-32.Buchwald H, Estok R, Fahrbach K. et al. Trends in mortality in bariatric surgery: a systematic review and meta-analysis. Surgery 2007;142:621-32.Buchwald H, Estok R, Fahrbach K. et al. Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. Am J Med 2009;122:249-61.Buchwald H, Estok R, Fahrbach K. et al. Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. Am J Med 2009;122:249-61.Buchwald H, Varco R. Metabolic Surgery. New York: Grune & Stratton 1978. chap 11.Buchwald H, Varco R. Metabolic Surgery. New York: Grune & Stratton 1978. chap 11.Сummings D, Overduin J, Foster-Schubert K. Gastric bypass for obesity: mechanisms of weight loss and diabetes resolution. J Clin Endocrinol Metab 2004;89:2608-15.Сummings D, Overduin J, Foster-Schubert K. Gastric bypass for obesity: mechanisms of weight loss and diabetes resolution. J Clin Endocrinol Metab 2004;89:2608-15.Drucker D. The biology of incretin hormones. Сell Metabolism 2006;3:153-65.Drucker D. The biology of incretin hormones. Сell Metabolism 2006;3:153-65.Drucker D. The role of gut hormones in glucose homeostasis. J Clin Invest 2007;117:24-32.Drucker D. The role of gut hormones in glucose homeostasis. J Clin Invest 2007;117:24-32.Ehses J, Casilla V, Doty T. et al. Glucose-dependent insulinotropic polypeptide promotes beta-cell survival via cyclic adenosine monophosphate-mediated caspase-3 inhibition and regulation of p-38 mitigen-activated protein kinase. Endocrinology 2003;144:4433-45.Ehses J, Casilla V, Doty T. et al. Glucose-dependent insulinotropic polypeptide promotes beta-cell survival via cyclic adenosine monophosphate-mediated caspase-3 inhibition and regulation of p-38 mitigen-activated protein kinase. Endocrinology 2003;144:4433-45.Elrick H, Stimmler L, Hlad C, Arai Y. Plasma insulin response to oral and intravenous glucose administration. J Clin Endocrinol Metab 1964;24:1076-82.Elrick H, Stimmler L, Hlad C, Arai Y. Plasma insulin response to oral and intravenous glucose administration. J Clin Endocrinol Metab 1964;24:1076-82.Holst J, Gromada J. Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans. Am J Physiol Endocrinol Metab 2004;287:E199-Е206.Holst J, Gromada J. Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans. Am J Physiol Endocrinol Metab 2004;287:E199-Е206.Holst J, Vislboll T, Deacon C. The incretin system and its role in type 2 diabetes mellitus. Mol Cell Endocrinol 2009;297:127-36.Holst J, Vislboll T, Deacon C. The incretin system and its role in type 2 diabetes mellitus. Mol Cell Endocrinol 2009;297:127-36.Kim W, Egan J. The role of incretins in glucose homeostasis and diabetes treatment. Pharmacol Rev 2008;60:470-512.Kim W, Egan J. The role of incretins in glucose homeostasis and diabetes treatment. Pharmacol Rev 2008;60:470-512.Laferrere B, Heshka S, Wang K et al. Incretin levels and effect are markedly enhanced 1 month after Roux-en-Y gastric bypass surgery in obese patients with type 2 diabetes. Diabetes Care 2007;30:1709-16.Laferrere B, Heshka S, Wang K et al. Incretin levels and effect are markedly enhanced 1 month after Roux-en-Y gastric bypass surgery in obese patients with type 2 diabetes. Diabetes Care 2007;30:1709-16.MacDonald K, Long S, Swanson M et al. The gastric bypass operation reduces the progression and mortality of non-insulin-dependent diabetes mellitus. J Gastrointest Surg 1997;1:213-20.MacDonald K, Long S, Swanson M et al. The gastric bypass operation reduces the progression and mortality of non-insulin-dependent diabetes mellitus. J Gastrointest Surg 1997;1:213-20.Mason E. The mechanism of type 2 diabetes. Obes Surg 2005;15:459-61.Mason E. The mechanism of type 2 diabetes. Obes Surg 2005;15:459-61.Moore B, Edie E, Abram J. On the treatment of diabetes mellitus by acid extract of duodenal mucosa membrane. Biochem J 1906;1:28-38.Moore B, Edie E, Abram J. On the treatment of diabetes mellitus by acid extract of duodenal mucosa membrane. Biochem J 1906;1:28-38.Naslund E, Bogefors J, Skogar S et al. GLP-1 slows solid gastric emptying and inhibits insulin, glucagon, and PYY release in humans. Am J Physiol 1999;277:R910-16.Naslund E, Bogefors J, Skogar S et al. GLP-1 slows solid gastric emptying and inhibits insulin, glucagon, and PYY release in humans. Am J Physiol 1999;277:R910-16.Nauck M. Unraveling the science of incretin biology. Am J Med 2009;122:S3-S10.Nauck M. Unraveling the science of incretin biology. Am J Med 2009;122:S3-S10.Nauck M, Kleine N, Űrskov C. et al. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in Type 2 (non-insulin-dependent) diabetic patients. Diabetologia 1993;36:741-44.Nauck M, Kleine N, Űrskov C. et al. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in Type 2 (non-insulin-dependent) diabetic patients. Diabetologia 1993;36:741-44.Nauck M, Stockmann F, Ebert R. et al. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia 1986;29:46-52.Nauck M, Stockmann F, Ebert R. et al. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia 1986;29:46-52.Neumiller J. Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors. J Am Pharm Assos 2009;49(1):S16-29.Neumiller J. Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors. J Am Pharm Assos 2009;49(1):S16-29.Nikolaidis L, Mankad S, Sokos G et al. Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation 2004;109(8):962-65.Nikolaidis L, Mankad S, Sokos G et al. Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation 2004;109(8):962-65.Perfetti R. The role of GLP-1 in the regulation of the islet cell mass. Medscape Diabet Endocrinol 2004;6(2):134-38.Perfetti R. The role of GLP-1 in the regulation of the islet cell mass. Medscape Diabet Endocrinol 2004;6(2):134-38.Perley M, Kipins D. Plasma insulin responces to oral and intravenous glucose: studies in normal and diabetic subjects. J Clin Invest 1967;46:1954-62.Perley M, Kipins D. Plasma insulin responces to oral and intravenous glucose: studies in normal and diabetic subjects. J Clin Invest 1967;46:1954-62.Pories W. Prevention and control of type 2 diabetes mellitus with gastric bypass surgery. International J Obesity 1998;22:S85.Pories W. Prevention and control of type 2 diabetes mellitus with gastric bypass surgery. International J Obesity 1998;22:S85.Pories W. Remission of type 2 diabetes mellitus following the gastric bypass operation: timing and magnitude of weight loss. Progress in obesity research: 8, Edited by B.Guy-Grand and G. Ailhaud Lohn Libbey & Company Ltd. 8th Internatuional Congress on Obesity 1999:511-16.Pories W. Remission of type 2 diabetes mellitus following the gastric bypass operation: timing and magnitude of weight loss. Progress in obesity research: 8, Edited by B.Guy-Grand and G. Ailhaud Lohn Libbey & Company Ltd. 8th Internatuional Congress on Obesity 1999:511-16.Pories W, Caro J, Flickinger E et al. The control of diabetes mellitus in the morbidly obese with the Greenville Gastric Bypass. Ann Surg 1987;206:316-23.Pories W, Caro J, Flickinger E et al. The control of diabetes mellitus in the morbidly obese with the Greenville Gastric Bypass. Ann Surg 1987;206:316-23.Pories W, Dohm G. Full and Durable Remission of Type 2 Diabetes? Through Surgery? Surg Obes Relat Dis 2009;5(2):285-88.Pories W, Dohm G. Full and Durable Remission of Type 2 Diabetes? Through Surgery? Surg Obes Relat Dis 2009;5(2):285-88.Pories W, MacDonald K, Flickinger E et al. Is type II diabetes mellitus a surgical disease? Ann Surg 1992;215(6):633-42.Pories W, MacDonald K, Flickinger E et al. Is type II diabetes mellitus a surgical disease? Ann Surg 1992;215(6):633-42.Pories W, Swanson M, MacDonald K et al. Who would have thought it? An operation proves to be the most effective therapy for adult onset diabetes mellitus. Ann Surg 1995;222:339-52.Pories W, Swanson M, MacDonald K et al. Who would have thought it? An operation proves to be the most effective therapy for adult onset diabetes mellitus. Ann Surg 1995;222:339-52.Ranganath L. The enteroinsular axis: implications for human metabolism. Clin Chem Lab Med 2008;46:43-56.Ranganath L. The enteroinsular axis: implications for human metabolism. Clin Chem Lab Med 2008;46:43-56.Rodieux F, Giusti V, D' Alessio D et al. Effects of gastric bypass and gastric banding on glucose kinetics and gut hormone release. Obesity (Silver Spring) 2008;16:298-305.Rodieux F, Giusti V, D' Alessio D et al. Effects of gastric bypass and gastric banding on glucose kinetics and gut hormone release. Obesity (Silver Spring) 2008;16:298-305.le Roux C, Welbourn R, Werling M et al. Gut hormones as mediators of appetite and weight loss after Roux-en-Y gastric bypass. Annals of Surgery 2007;246(5):780-85.le Roux C, Welbourn R, Werling M et al. Gut hormones as mediators of appetite and weight loss after Roux-en-Y gastric bypass. Annals of Surgery 2007;246(5):780-85.Rubino F, Gagner M. Potencial of surgery for curing type 2 diabetes mellitus. Ann Surg 2002;236:554-59.Rubino F, Gagner M. Potencial of surgery for curing type 2 diabetes mellitus. Ann Surg 2002;236:554-59.Salinari S, Bertuzzi A, Asnaghi S et al. First-phase insulin secretion restoration and differential response to glucose load depending on the route of administration in type 2 diabetic subjects after bariatric surgery. Diabetes Care 2009;32:375-80.Salinari S, Bertuzzi A, Asnaghi S et al. First-phase insulin secretion restoration and differential response to glucose load depending on the route of administration in type 2 diabetic subjects after bariatric surgery. Diabetes Care 2009;32:375-80.Schmidt W, Siegel E, Creutzfeld W. Glucagon-like peptide-1 but not glucagon-like peptide-2 stimulates insulin release from isolated rat pancreatic islets. Diabetologia 1985;28:704-7.Schmidt W, Siegel E, Creutzfeld W. Glucagon-like peptide-1 but not glucagon-like peptide-2 stimulates insulin release from isolated rat pancreatic islets. Diabetologia 1985;28:704-7.Scopinaro N, Papadia F, Camerini G et al. A comparison of a personal series of biliopancreatic diversion and literature data on gastric bypass help to explain the mechanisms of resolution of type 2 diabetes by the two operations. Obes Surg 2008;18:1035-38.Scopinaro N, Papadia F, Camerini G et al. A comparison of a personal series of biliopancreatic diversion and literature data on gastric bypass help to explain the mechanisms of resolution of type 2 diabetes by the two operations. Obes Surg 2008;18:1035-38.Sjostrom L, Lindroos A, Peltonen M et al. Swedish Obese Subjects Study Scientific Group. Lifestyle, diabetes and cardiovascular risk factors 10 years after bariatric surgery. N Eng J Med 2004;351: 2683-93.Sjostrom L, Lindroos A, Peltonen M et al. Swedish Obese Subjects Study Scientific Group. Lifestyle, diabetes and cardiovascular risk factors 10 years after bariatric surgery. N Eng J Med 2004;351: 2683-93.Toft-Nielsen M, Damholt M, Madsbad S et al. Determinats of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J Clin Endocrinol Metab 2001;86:3717-23.Toft-Nielsen M, Damholt M, Madsbad S et al. Determinats of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J Clin Endocrinol Metab 2001;86:3717-23.Vilsboll T, Krarup T, Deacon C et al. Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes 2001;50:609-13.Vilsboll T, Krarup T, Deacon C et al. Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes 2001;50:609-13.Wideman R, Kieffer T. Glucose-dependent insulinotropic polypeptide as a regulator of beta cell function and fate. Hormone and metabolic research 2004;36:782-86.Wideman R, Kieffer T. Glucose-dependent insulinotropic polypeptide as a regulator of beta cell function and fate. Hormone and metabolic research 2004;36:782-86.

The authors declare that there are no conflicts of interest present.